Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 53.27 +0.39 (+0.74%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sanofi-Aventis S.A. ADR < Previous 1 2 3 Next > Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD September 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) September 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges September 24, 2024 Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? Via MarketBeat Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old September 20, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Biotech Breakout: Stocks for Your Watchlist September 12, 2024 The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. Via MarketBeat Topics ETFs Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial September 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp? August 12, 2024 Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Via MarketBeat Exposures COVID-19 BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model August 08, 2024 Via Investor Brand Network Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities August 06, 2024 EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END Via FinancialNewsMedia Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities August 06, 2024 From FN Media Group LLC Via GlobeNewswire Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation May 31, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Is DoubleVerify’s 39% Haircut a Buying Opportunity? May 15, 2024 Digital advertising verification and measurement solutions provider DoubleVerify Holdings Inc. (NYSE: DV) shares took a 39% plunge on its Q1 2024 earnings Via MarketBeat Topics Artificial Intelligence Fraud Malware Exposures Artificial Intelligence Information Security Legal Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 May 13, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy May 13, 2024 From Fulcrum Therapeutics, Inc. Via GlobeNewswire Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) May 13, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024 April 30, 2024 From Pinnacle Group International Via ACN Newswire Novo Nordisk Arms Wegovy to Be a Triple Threat April 15, 2024 Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders Via MarketBeat 6 reasons to buy Teva Pharmaceuticals stock sooner than later February 26, 2024 Investors seeking a long-term and undervalued pharmaceutical play should take a close look at Teva Pharmaceuticals, and here are six reasons why Via MarketBeat Topics Lawsuit Exposures Financial Legal Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) January 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Time to buy these 3 healthcare companies that raised revenue guidance? January 16, 2024 The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. Via MarketBeat Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment November 30, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Teva Pharma is the way to play the re-rise of generic drugs November 28, 2023 Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth Via MarketBeat Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease November 27, 2023 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire MarketBeat Week in Review – 11/6 - 11/10 November 11, 2023 Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Pfizer and Sanofi shares fall, which one to scoop up? November 07, 2023 Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows Via MarketBeat Exposures COVID-19 Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 Via Investor Brand Network Get Ready for Next Generation of Diabetes, Weight-Management Drugs November 01, 2023 EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END Via FinancialNewsMedia < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
